SRRK · Scholar Rock Holding Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $51.81M | - | $50.49M | $62.40M | $48.68M | - | $48.72M | $42.37M | $43.09M | - |
| SG&A | $50.20M | - | $53.06M | $49.71M | $28.41M | - | $16.06M | $17.13M | $15.32M | - |
| Total Operating Expenses | $102.02M | - | $103.55M | $112.11M | $77.09M | - | $64.78M | $59.50M | $58.42M | - |
| D&A | $335.0K | - | - | - | $393.0K | - | - | - | $598.0K | - |
| Operating Income | ($102.02M) | - | ($103.55M) | ($112.11M) | ($77.09M) | - | ($64.78M) | ($59.50M) | ($58.42M) | - |
| Interest Expense | $2.30M | - | $1.33M | $1.72M | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($105.51M) | - | ($102.22M) | ($110.03M) | ($74.72M) | - | ($64.48M) | ($58.51M) | ($56.85M) | - |
| EPS - Basic | ($0.83) | - | ($0.90) | ($0.98) | ($0.67) | - | ($0.66) | ($0.60) | ($0.59) | - |
| EPS - Diluted | ($0.83) | - | ($0.90) | ($0.98) | ($0.67) | - | ($0.66) | ($0.60) | ($0.59) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $430.54M | $323.53M | $286.77M | $152.93M | $137.93M | $177.88M | $76.39M | $93.37M | $91.98M | $101.86M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $9.22M | $10.30M | $6.76M | $1.10M | $4.44M | $10.10M | $4.07M | $3.31M | $2.87M | $3.46M |
| Current Assets | $515.28M | $385.15M | $390.71M | $319.13M | $385.25M | $451.17M | $152.93M | $199.14M | $246.93M | $288.19M |
| Total Assets | $535.25M | $404.27M | $411.72M | $340.05M | $407.55M | $474.92M | $179.13M | $226.87M | $267.29M | $311.04M |
| Current Liabilities | $59.64M | $55.42M | $61.97M | $50.44M | $37.57M | $46.94M | $39.37M | $32.99M | $37.51M | $32.74M |
| Long-term Debt | $196.61M | $99.71M | $99.61M | $49.76M | $49.74M | $50.15M | $50.10M | $48.48M | $44.59M | $48.68M |
| Total Liabilities | $259.24M | $158.78M | $166.72M | $106.75M | $95.22M | $106.29M | $99.94M | $93.25M | $84.51M | $85.82M |
| Stockholders' Equity | $276.01M | $245.49M | $245.00M | $233.29M | $312.33M | $368.63M | $79.20M | $133.62M | $182.77M | $225.22M |
| Retained Earnings | ($1.41B) | ($1.30B) | ($1.21B) | ($1.11B) | ($997.44M) | ($922.72M) | ($856.26M) | ($791.78M) | ($733.27M) | ($676.42M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($82.10M) | - | - | - | ($78.67M) | - | - | - | ($49.78M) | - |
| Investing Cash Flow | ($5.33M) | - | - | - | $34.55M | - | - | - | $33.38M | - |
| Financing Cash Flow | $193.79M | - | - | - | $4.17M | - | - | - | $6.53M | - |
| CapEx | $68.0K | - | - | - | $271.0K | - | - | - | $23.0K | - |
| Free Cash Flow | ($82.17M) | - | - | - | ($78.95M) | - | - | - | ($49.81M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.78 | - | - | - | 1.06 | - | - | - | 0.88 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -19.7% | - | -24.8% | -32.4% | -18.3% | - | -36.0% | -25.8% | -21.3% | - |
| Return on equity | -38.2% | - | -41.7% | -47.2% | -23.9% | - | -81.4% | -43.8% | -31.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 8.64 | 6.95 | 6.30 | 6.33 | 10.25 | 9.61 | 3.88 | 6.04 | 6.58 | 8.80 |
| Quick ratio | 8.64 | 6.95 | 6.30 | 6.33 | 10.25 | 9.61 | 3.88 | 6.04 | 6.58 | 8.80 |
| Cash ratio | 7.22 | 5.84 | 4.63 | 3.03 | 3.67 | 3.79 | 1.94 | 2.83 | 2.45 | 3.11 |
| Leverage | ||||||||||
| Debt / Equity | 0.71 | 0.41 | 0.41 | 0.21 | 0.16 | 0.14 | 0.63 | 0.36 | 0.24 | 0.22 |
| Debt / Assets | 0.37 | 0.25 | 0.24 | 0.15 | 0.12 | 0.11 | 0.28 | 0.21 | 0.17 | 0.16 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -44.3x | - | -77.6x | -65.4x | - | - | - | - | - | - |
| Equity multiplier | 1.94 | 1.65 | 1.68 | 1.46 | 1.30 | 1.29 | 2.26 | 1.70 | 1.46 | 1.38 |
| Liabilities / Assets | 0.48 | 0.39 | 0.40 | 0.31 | 0.23 | 0.22 | 0.56 | 0.41 | 0.32 | 0.28 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 22.7x | - | 17.3x | 17.1x | 11.5x | - | 9.8x | 6.0x | 9.3x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -32.3% | - | -59.8% | -88.4% | -32.0% | - | -48.3% | -52.2% | -44.2% | - |
| Net income growth (YoY) | -41.2% | - | -58.5% | -88.1% | -31.4% | - | -52.2% | -54.3% | -44.4% | - |
| EPS growth (YoY) | -23.9% | - | -36.4% | -63.3% | -13.6% | - | -24.5% | -27.7% | -20.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -4.1% | - | - | - | -58.5% | - | - | - | -15.6% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -11.6% | -33.4% | 209.4% | 74.6% | 70.9% | 63.7% | -52.8% | -34.0% | -20.1% | -13.5% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Scholar Rock Holding Corp against the 5 most active filers in the same SIC group.